$2.410
+0.160 (+6.64%)收盤時
RADX 同業比較
In the context of the broader market, RADX competes directly with industry leaders such as DCGO and EUDA. With a market capitalization of $34.84M, it holds a significant position in the sector. When comparing efficiency, RADX's gross margin of N/A stands against DCGO's 26.85% and EUDA's 43.77%. Such benchmarking helps identify whether Radiopharm Theranostics Ltd is trading at a premium or discount relative to its financial performance.
Radiopharm Theranostics Ltd 財務表現
The company has a price-to-sales ratio of 1.094 and a price-to-book ratio of 0.344, indicating that the stock may be undervalued relative to its sales and assets. However, the negative P/E ratio and forward P/E of 0 suggest that the company is currently not profitable, which could be a concern for long-term investors.
Financials
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。